What does this research mean for the field?

In patients with atopic dermatitis, upadacitinib provides greater early pruritus relief than abrocitinib, although both selective JAK inhibitors demonstrate comparable overall skin lesion clearance with lower efficacy in the head and neck region. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare the real-world clinical effectiveness and anatomical site-specific clearance of abrocitinib versus upadacitinib in patients with atopic dermatitis.

September 8, 2026Journal of Dermatological TreatmentOpen Access

Real-world effectiveness of abrocitinib and upadacitinib in atopic dermatitis: a propensity-matched analysis

View Full Paper

Ask AI

Bookmark

Authors

RWRuojun WangNational Skin Centre ZYZhihui YangNational Skin Centre HLHang LiNational Skin Centre

Discussion

Member takes

Overview

Retrospective cohort study reveals faster itch relief with upadacitinib than abrocitinib in atopic dermatitis, suggesting differential early symptom control despite similar overall skin clearance.

Key Points

To compare the real-world clinical effectiveness and anatomical site-specific clearance of abrocitinib versus upadacitinib in patients with atopic dermatitis.
Retrospective multicenter cohort study analyzing patient records from the CORNERSTONE database.
Propensity score matching was conducted to balance baseline characteristics, yielding 282 patients in each treatment cohort.
EASI-75 and EASI-90 skin clearance rates showed no significant between-group differences from week 2 through week 12.
A significantly greater proportion of patients achieved a PP-NRS4 itch reduction response at week 2 in the upadacitinib group compared to the abrocitinib group (p < 0.001).
Both abrocitinib and upadacitinib exhibited lower EASI-75 response rates in the head and neck region than in other body regions at week 12.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd80458e84d0ff5b4726d https://doi.org/10.1080/09546634.2026.2713289

View Full Paper

Ask AI

Bookmark

September 8, 2026Journal of Dermatological TreatmentOpen Access

Real-world effectiveness of abrocitinib and upadacitinib in atopic dermatitis: a propensity-matched analysis

View Full Paper

Ask AI

Bookmark

Authors

RWRuojun WangNational Skin Centre ZYZhihui YangNational Skin Centre HLHang LiNational Skin Centre

Discussion

Member takes

Overview

Retrospective cohort study reveals faster itch relief with upadacitinib than abrocitinib in atopic dermatitis, suggesting differential early symptom control despite similar overall skin clearance.

Key Points

To compare the real-world clinical effectiveness and anatomical site-specific clearance of abrocitinib versus upadacitinib in patients with atopic dermatitis.
Retrospective multicenter cohort study analyzing patient records from the CORNERSTONE database.
Propensity score matching was conducted to balance baseline characteristics, yielding 282 patients in each treatment cohort.
EASI-75 and EASI-90 skin clearance rates showed no significant between-group differences from week 2 through week 12.
A significantly greater proportion of patients achieved a PP-NRS4 itch reduction response at week 2 in the upadacitinib group compared to the abrocitinib group (p < 0.001).
Both abrocitinib and upadacitinib exhibited lower EASI-75 response rates in the head and neck region than in other body regions at week 12.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd80458e84d0ff5b4726d https://doi.org/10.1080/09546634.2026.2713289

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark